Cboe - Market News Story
GlycoMimetics Reports Enrollment Completed For Phase 3 Trial Evaluating Rivipansel In Sickle Cell Disease

Benzinga Newsdesk 5/6/2019 8:08:51 AM

Attachments

  • Original document
  • Permalink

Disclaimer

CBOE Holdings Inc. published this content on 06 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 06 May 2019 13:47:01 UTC